Quarterly results
- Natera's Q2 revenue grew 38%, beating analyst expectations.
- The genetic testing firm's Q2 net loss narrowed to $67 million from $101 million a year earlier.
- Q2 loss per share was $0.47.
Outlook raised for 2026
- Natera raised its 2026 annual revenue guidance to $2.85 billion-$2.91 billion.
- The company expects 2026 gross margin of 64% to 66%.
- Natera forecasts positive cash flow for 2026.
What drove the increase
- Revenue growth was driven by higher overall test volumes, including a 22% rise in tests processed year over year.
- Oncology test volumes rose 57% year over year, with MRD oncology units posting the largest sequential increase to date.
- Higher gross margin was attributed to increased revenue and continued progress in reducing cost of revenues for tests processed.
Analyst and valuation context
NTRA•
